Open AccessBurden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study
Author(s) -
Saro H. Armenian,
Yanjun Chen,
Lindsay Hageman,
Jessica Wu,
Wendy Landier,
Alysia Bosworth,
Liton Francisco,
Elizabeth Schlichting,
Ravi Bhatia,
Donna Salzman,
F. Lennie Wong,
Daniel J. Weisdorf,
Stephen J. Forman,
Mukta Arora,
Smita Bhatia
Publication year - 2022
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.21.02829
Subject(s) - medicine , odds ratio , myeloid leukemia , transplantation , cumulative incidence , population , pediatrics , environmental health
Blood or marrow transplantation (BMT) is an integral part of consolidation and/or salvage therapy for patients with acute myeloid leukemia (AML). With the growing population of AML survivors, there is a need to understand the quality of their survival.